KLDO (Kaleido Biosciences) LT-Debt-to-Total-Asset: 0.11 (As of Dec. 2021)


What is Kaleido Biosciences LT-Debt-to-Total-Asset?

Kaleido Biosciences KLDO -99.00% LT-Debt-to-Total-Asset is 0.11 as of Dec. 2021.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Kaleido Biosciences's long-term debt to total assests ratio for the quarter that ended in Dec. 2021 was 0.11.

Kaleido Biosciences's long-term debt to total assets ratio declined from Dec. 2020 (0.31) to Dec. 2021 (0.11). It may suggest that Kaleido Biosciences is progressively becoming less dependent on debt to grow their business.

Kaleido Biosciences  (OTCPK:KLDO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Kaleido Biosciences LT-Debt-to-Total-Asset Related Terms

Kaleido Biosciences LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Kaleido Biosciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaleido Biosciences LT-Debt-to-Total-Asset Chart

Kaleido Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.48 0.17 0.25 0.31 0.11

Kaleido Biosciences Quarterly Data
Dec16 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.16 0.21 0.22 0.11

Kaleido Biosciences LT-Debt-to-Total-Asset Calculation

Kaleido Biosciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

LT Debt to Total Assets (A: Dec. 2021 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2021 )/Total Assets (A: Dec. 2021 )
=5.55/50.137
=0.11

Kaleido Biosciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2021 is calculated as

LT Debt to Total Assets (Q: Dec. 2021 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2021 )/Total Assets (Q: Dec. 2021 )
=5.55/50.137
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.11 mean?
Kaleido Biosciences (KLDO) has a LT-Debt-to-Total-Asset of 0.11 as of Dec. 2021. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Kaleido Biosciences and its competitors.
Is Kaleido Biosciences' LT-Debt-to-Total-Asset too high?
Kaleido Biosciences' current LT-Debt-to-Total-Asset is 0.11.
How does Kaleido Biosciences' LT-Debt-to-Total-Asset compare to NPTX and GSTC?
Kaleido Biosciences' LT-Debt-to-Total-Asset of 0.11 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Kaleido Biosciences and its competitors. Kaleido Biosciences's current LT-Debt-to-Total-Asset is 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaleido Biosciences stock overvalued right now?
Kaleido Biosciences (KLDO) has a current LT-Debt-to-Total-Asset of 0.11. The current LT-Debt-to-Total-Asset is 0.11. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Kaleido Biosciences (KLDO), the current LT-Debt-to-Total-Asset is 0.11 as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kaleido Biosciences Business Description

Address 65 Hayden Avenue, Lexington, MA, USA, 02421
Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.